Ranbaxy Laboratories has decided to voluntarily discontinue the marketing of Valdecoxib with immediate effect. According to a company statement, the decision was made after US FDA asked Pfizer to suspend the sales of its arthritis drug, Bextra (Valdecoxib), due to unfavourable risk benefit ratio.
"The Company's decision is in conformity with its firm commitment to ethical business conduct. All patients presently consuming Ranbaxy's Valdecoxib formulations should consult their physicians for alternate and appropriate medications/treatment options," the statement said.